Financial Challenges of Long-Term Cancer Medications
Author Information
Author(s): Elshiekh Cleopatra, Rudà Roberta, Cliff Edward R, Gany Francesca, Budhu Joshua A
Primary Institution: Memorial Sloan Kettering Cancer Center
Hypothesis
How do high costs of long-term targeted therapies impact patient access and financial toxicity?
Conclusion
The introduction of vorasidenib may improve patient outcomes but could also exacerbate financial toxicity without proper cost-management strategies.
Supporting Evidence
- High costs of targeted cancer therapies can exceed $150,000 annually.
- Financial toxicity can lead to medical debt, income loss, and psychological stress.
- Many cancer patients face substantial out-of-pocket expenses and potential treatment abandonment.
Takeaway
Some cancer medicines are really expensive, and if patients can't afford them, they might skip doses or stop taking them altogether, which can make their health worse.
Methodology
This review analyzes drug approval and pricing mechanisms in various countries and their impact on healthcare costs and patient access.
Limitations
The review does not provide specific data on the financial impact of vorasidenib as it has not yet been priced.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website